
|Articles|October 8, 2012
FDA gives green light to ANDA for chewable diabetes tablet
FDA has approved Boston Therapeutic’s petition to file an Abbreviated New Drug Application (ANDA) for a new, chewable tablet formulation of the diabetes drug metformin hydrochloride. The company plans to market the new formulation under the name Pazamet.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
The Pharmacist’s Expertise in Managing Pneumococcal Diseases, Vaccines
2
What TrumpRx Means for Independent Pharmacies and Their Patients
3
Addressing Clinical Challenges and Expanding Pharmacy Roles | Recap ASHP Midyear 2025
4
Oral Semaglutide Show Promise as New Benchmark for Diabetes Care, Cardiovascular Protection
5






























































































































